期刊
NPJ BREAST CANCER
卷 8, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41523-022-00483-1
关键词
-
类别
资金
- Radius Health
- NHS
- Arthur Foundation
- Breast Cancer Now
This study found that the novel SERD drug elacestrant has potential therapeutic effects on breast cancer, showing activity in patients with ESR1 mutations and responding to acquired resistance to fulvestrant. Elacestrant has a similar impact on estrogen receptor activity, cell proliferation, and transcription as fulvestrant. Additionally, combining elacestrant with CDK4/6 inhibitors enhances the anti-proliferative effect.
The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral bioavailability. Comparison of the orally bioavailable investigational SERD elacestrant, versus fulvestrant, demonstrates both drugs impact tumour growth of ER+ patient-derived xenograft models harbouring several ESR1 mutations but that elacestrant is active after acquired resistance to fulvestrant. In cell line models of endocrine sensitive and resistant breast cancer both drugs impact the ER-cistrome, ER-interactome and transcription of oestrogen-regulated genes similarly, confirming the anti-oestrogenic activity of elacestrant. The addition of elacestrant to CDK4/6 inhibitors enhances the antiproliferative effect compared to monotherapy. Furthermore, elacestrant inhibits the growth of palbociclib-resistant cells. Lastly, resistance to elacestrant involves Type-I and Type-II receptor tyrosine kinases which are amenable to therapeutic targeting. Our data support the wider clinical testing of elacestrant.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据